Quantltation of serum complement components and plasma C3d in patients with malignant lymphoma: Relation to the stage of the tumor and circulating immune complexes

Total hemolytic complement activity (CH 50) and complement component levels were measured in 27 patients with Hodgkin's disease and 31 patients with non‐Hodgkin malignant lymphoma. CH 50 values were higher than normal in almost alt the patients. Increased levels of serum C4, C3 and factor B were observed in 62%, 31% and 19% of these patients, respectively. However, plasma concentration of C3d, a breakdown product of C3, was elevated in 29% of the cases. The hypercatabolism of C3 was nat closely associated with the presence of circulating immune complexes, as assessed by the Clq binding assay, nor with the presence of general symptoms in the patients. On the contrary, it appeared to be in relation with the extent of the malignant disease.

[1]  P. Lambert,et al.  Circulating immune complexes in patients with malignant lymphomas and solid tumors , 1977, International journal of cancer.

[2]  D. Bitter‐Suermann,et al.  Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. , 1977, Immunology.

[3]  R. Rossen,et al.  The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. , 1977, Journal of the National Cancer Institute.

[4]  A. Theofilopoulos,et al.  Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway. , 1977, Science.

[5]  R. Zubler,et al.  Immune complexes and complement hypercatabolism in patients with leprosy. , 1976, Clinical and experimental immunology.

[6]  M. Mardiney,et al.  Abnormalities of complement and its components in patients with acute leukemia, Hodgkin's disease, and sarcoma. , 1976, Cancer research.

[7]  G. Klein,et al.  Circulating immune complexes in sera of patients with Burkitt's lymphoma and nasopharyngeal carcinoma , 1976, International journal of cancer.

[8]  B. Williams,et al.  CIRCULATING IMMUNE COMPLEXES AND SYMPTOMS IN HODGKIN'S DISEASE , 1976, The Lancet.

[9]  P. Lambert,et al.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. , 1975, The Journal of clinical investigation.

[10]  H. Stalsberg,et al.  [Histologic classification of malignant lymphoma--a national standard]. , 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[11]  R. Lukes,et al.  Immunologic characterization of human malignant lymphomas , 1974, Cancer.

[12]  P. Lambert,et al.  Detection of anti-glomerular basement membrane antibodies by radioimmunological technique. Clinical application in human nephropathies. , 1974, The Journal of clinical investigation.

[13]  M. Etievant.  [Alternate pathway activation of the complement system]. , 1973, Pathologie-biologie.

[14]  W. König,et al.  Bypass-activation of the complement system starting with C3. II. C3-activation by gamma-1-immune aggregates in guinea pig serum. , 1973, Immunochemistry.

[15]  I. Gigli,et al.  The complement system of man. 3. , 1972, The New England journal of medicine.

[16]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[17]  V. Devita,et al.  Report of the Committee on Hodgkin's Disease Staging Procedures. , 1971, Cancer research.

[18]  D. McKenzie,et al.  Complement reactivity of cancer patients: measurements by immune hemolysis and immune adherence. , 1967, Cancer research.

[19]  L. Craver,et al.  Report of the Nomenclature Committee , 1966 .

[20]  R. Lukes,et al.  The pathology and nomenclature of Hodgkin's disease. , 1966, Cancer research.

[21]  R. Zarco,et al.  SERUM COMPLEMENT LEVELS IN HUMAN CANCER. , 1964, Journal of the Philippine Medical Association.

[22]  P. Bunn,et al.  Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas. , 1960, The Journal of laboratory and clinical medicine.

[23]  A. Levy,et al.  Behavior of total serum complement in Hodgkin's disease and other malignant lymphomas. , 1959, Blood.

[24]  M. Abrahamson.  Pulmonocardiac failure associated with deformity of the chest. , 1959, Lancet.

[25]  G. Invernizzi.  [Tumors of the hemopoietic system]. , 1955, Rassegna clinico-scientifica.

[26]  A. Theofilopoulos,et al.  The Raji cell radioimmune assay for detecting immune complexes in human sera. , 1976, The Journal of clinical investigation.

[27]  R. Zubler,et al.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. , 1976, Journal of immunology.

[28]  I. Gigli,et al.  The complement system of man. I. , 1972, The New England journal of medicine.

[29]  P. Schur,et al.  Complement in human disease. , 1968, Annual review of medicine.

[30]  J. LeonardLichtenfeld.  Abnormalities of Complement and Its Components in Patients with Acute Leukemia , Hodgkin ' s Disease , and Sarcoma , 2022 .